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Previous studies have shown that repeated application of
TRAIL induces acquired resistance to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL). Using human pros-
tate adenocarcinomaDU-145 and human pancreatic carcinoma
MiaPaCa-2 cells as a model, we now demonstrate for the first
time that two states of acquired TRAIL resistance can be devel-
oped afterTRAIL treatment.Data fromsurvival assay andWest-
ern blot analysis show that acquired TRAIL resistance was
developed within 1 day and gradually decayed within 6 days
after TRAIL treatment in both cell lines. After TRAIL treat-
ment, the level of Bcl-xL increased and reached a maximum
within 2 days and gradually decreased in both cell lines. Bcl-xL-
mediated development of acquired TRAIL resistance was sup-
pressed by knockdownof Bcl-xL expression. Protein interaction
assay revealed that during the development of TRAIL resist-
ance, Bcl-xL dissociated fromBad and then associatedwith Bax.
Overexpression of mutant-type Bad (S136A), which prevents
this dissociation, partially suppressed the development of
acquired TRAIL resistance. Thus, our results suggest that (a)
dissociation of Bad from Bcl-xL and (b) an increase in the intra-
cellular level of Bcl-xL are responsible for development of
acquired TRAIL resistance.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)2 is a membrane-bound cytokine molecule that plays a
critical role as an inducer of apoptosis in a variety of cancer cells
in vitro and has been shown to limit tumor growth efficiently in
vivo, withminimal damage to normal tissues (1–3). It is thought
that TRAIL induces apoptosis by binding to the death receptors
TRAIL-R1 (DR4) and TRAIL-R2 (DR5), members of the tumor
necrosis factor receptor superfamily, which results in confor-
mational changes that expose a binding surface for Fas-associ-
ated death domain, an adaptor protein (4, 5). The adaptor mol-
ecule recruits the initiators caspase-8 and -10 to promote
formation of the death-inducing signaling complex (DISC).
The activation of caspases has been documented by several
observations, providing evidence that caspase-8, an initiator
caspase, cleaves Bid and triggers mitochondrial damage and
subsequently induces the release of cytochrome c from the
mitochondria (6). Cytochrome c in the cytoplasm binds to
Apaf-1, which then permits recruitment of procaspase-9 to
form the apoptosome protein complex. The formation of the
apoptosome results in the activation of caspase-9. Caspase-9
cleaves and activates procaspase-3 (7). This results in the acti-
vation of effector caspases such as caspase-3. Caspase-3 plays
an important role in both death receptor- and mitochondria-
mediated apoptosis (8). Previous studies have shown that
caspase-3 is required for the DNA fragmentation and mem-
brane blebbing associated with apoptosis (9). MCF-7, a breast
cancer cell line, is caspase-3-deficient (9) and relatively insen-
sitive to many chemotherapeutic agents (10). Reconstitution of
caspase-3 sensitizes MCF-7 cells to TRAIL (11).
Although the unique feature of selectivity for cancer cells has
drawn considerable attention toTRAIL as a potential therapeu-
tic agent against human cancers, the physiological role of
TRAIL is certainly more complex than merely activating the
caspase-dependent apoptosis of cancer cells (12–17). Previous
studies have shown that repeated application of TRAIL induces
acquired resistance to TRAIL (18). Several possible molecular
mechanisms have been suggested for cellular resistance to
TRAIL-induced apoptotic death (19). One possibility is dys-
functions of DR4 and DR5. Mutations in these receptors can
lead to a loss of their functions and result in suppression of
apoptosis (20–25). Another possibility is defects in the DISC
(26–28). A third possibility is a defect of effector caspases such
as caspase-3. Finally, a fourth possibility is that changes in pro-
teins which affect caspase activation may produce TRAIL
resistance. This includes the mutational inactivation of pro-
apoptotic molecules (Bax, Bak, Bad, Bim, or Bid) or the overex-
pression of death inhibitors (FLIP, FAP-1, Bcl-2, Bcl-xL, or
inhibitor of apoptosis (IAP)). These death inhibitors operate by
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several different mechanisms. The anti-apoptotic molecules of
the Bcl-2 family (Bcl-2, Bcl-xL) heterodimerize with pro-apo-
ptoticmembers of the Bcl-2 family (Bax, Bak) and interferewith
release of cytochrome c by pore-forming proteins (Bid, Bik)
(29). Members of the IAP family (c-IAP1, c-IAP2, XIAP)
directly bind and inhibit activation of caspases including
caspase-3, -7, and -9 (30). Two endogenous forms of FLIP
detected on the protein level, FLIPL and FLIPS (31, 32), prevent
caspase-8 activation at different stages of procaspase-8 process-
ing at the DISC (33). Thus, the overexpression of these anti-
apoptotic Bcl-2 family, IAP family, and FLIP family proteins or
loss of pro-apoptotic Bcl-2 family proteins can result in TRAIL
resistance.
In this study we investigated possible mechanisms for
acquired resistance to TRAIL. We observed that repeated
application of TRAIL induced acquired TRAIL resistance that
is transient and is developed through two differentmodes, acti-
vation of Bcl-xL and increase in the intracellular level of Bcl-xL.
EXPERIMENTAL PROCEDURES
Cell Culture and Survival Assay—Humanprostate adenocar-
cinomaDU-145 cells and human pancreatic cancerMiaPaCa-2
cells were cultured inDulbecco’smodified Eagle’smediumwith
10% fetal bovine serum (HyClone, Logan, UT) and 26 mM
sodium bicarbonate for monolayer cell culture. The cells were
maintained in a humidified atmosphere containing 5%CO2 and
air at 37 °C. For trypan blue exclusion assay (34), trypsinized
cells were pelleted and resuspended in 0.2ml ofmedium, 0.5ml
of 0.4% trypan blue solution, and 0.3 ml of phosphate-buffered
saline solution (PBS). The samples were mixed thoroughly,
incubated at room temperature for 15 min, and examined
FIGURE 1. TRAIL-induced cytotoxicity in human prostate adenocarci-
noma DU-145 cells. Cells were treated with TRAIL (200 ng/ml) for various
times (0–24 h). A, morphological features of each cell were analyzed with a
phase-contrast inverted microscope. Con, control. B, cell lysates were sub-
jected to immunoblotting for PARP. Immunoblots of PARP show the 116-kDa
PARP and the 85-kDa apoptosis-related cleavage fragment. Actinwas used to
confirm the amount of proteins loaded in each lane.
FIGURE 2. Effect of repeated TRAIL treatment on survival and proteolytic
cleavage of PARP in DU-145 cells (A and B) or human pancreatic carci-
nomaMia PaCa-2 cells (C).Cells were first treatedwith TRAIL (200 ng/ml) for
4 h, and then detached cells were removed by washing with PBS. After
removal of the detached cells, fresh media were added onto the remaining
attached cells and incubated for the time indicated (0–4 h or 1–6 d) and then
treated a second time with TRAIL (200 ng/ml) for 4 h. Cell survival was deter-
mined by trypan blue exclusion assay (upper panel), and cell lysates were sub-
jected to immunoblotting forPARPoractin (lowerpanels).Con, untreatedcontrol
cells. Error bars represent the S.E. from three separate experiments. t, time.
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under a light microscope. At least 300 cells were counted for
each survival determination.
Reagents and Antibodies—Anti-cIAP-1 and anti-cIAP-2
were purchased from R&D Systems (Minneapolis, MN).
Anti-Flip antibody was purchased from EMD Biosciences
(San Diego, CA). Anti-PARP was purchased from Biomol
(PlymouthMeeting, PA). Anti-caspase-8, anti-phospho-Ser-
473-Akt, anti-Akt, anti-Bad, and anti-phospho-Ser-136-Bad
were purchased from Cell Signaling (Beverly, MA). Anti-Bcl-
xL, anti-Bcl2, anti-Bax, anti-caspase-9, and anti-caspase-3 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-actin was purchased from ICN (Costa Mesa, CA), and
other chemicals were purchased from Sigma-Aldrich.
Production of Recombinant TRAIL—Ahuman TRAIL cDNA
fragment (amino acids 114–281) obtained by reverse transcrip-
tion-PCR was cloned into pET-23d (Novagen, Madison, WI)
plasmid, and His-tagged TRAIL protein was purified using the
Qiaexpress protein purification system (Qiagen, Valencia, CA).
RNA Interference by siRNA of
Bcl-xL—To stably express siRNA
for the long-term knockdown,
pSilencer 2.1-U6 hygro vector
(Ambion, Inc., Austin, TX)was used
for clonal cell lines. The inserts for
hairpin siRNA into pSilencer were
prepared by annealing two oligonu-
cleotides. For human Bcl-xL siRNA,
the top strand sequence was 5-
GATCCAGGATACAGCTGGAG-
TCAGTTCAAGAGACTGACTC-
CAGCTGTATCCTTTTTTTGG-
AAA-3, and the bottom strand
sequence was 5-AGCTTTTCCAA-
AAAAAGGATACAGCTGGAGT-
CAGTCTCTTGAACTGACTCCA-
GCTGTATCCT-3. The annealed
insert was cloned into pSilencer
2.1-U6 hygro digested with BamHI
and HindIII. The correct structure
of pSilencer 2.1-U6 hygro-Bcl-xL
was confirmed by nucleotide
sequencing. The resultant plasmid,
pSilencer-Bcl-xL, was transfected
into DU-145 cells, and hygromycin
B (250 g/ml)-resistant cell clones
were isolated. The interference of
Bcl-xL protein expression was con-
firmed by immunoblot using anti-
Bcl-xL antibody.
Transfection—To generate Bcl-xL
overexpressing DU-145 cells, cells
were transfected with 2 g of
pcDNA3-neo or pcDNA3-Flag-
Bcl-xL, which was kindly provided
by Dr. G. Nunez (University of
Michigan, Ann Arbor, MI), using
Lipofectamine Plus (Invitrogen).
The expression level was deter-
mined by immunoblot analysis.
Protein Extracts and PAGE—Cells were lysed with 1 Lae-
mmli lysis buffer (2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M
sodium dodecyl sulfate, 0.3 mM bromphenol blue) and boiled
for 10 min. Protein content was measured with BCA protein
assay reagent (Pierce). The samples were diluted with 1 lysis
buffer containing 1.28 M -mercaptoethanol, and equal
amounts of protein were loaded on 8–12% SDS-polyacrylam-
ide gels. SDS-PAGE analysis was performed according to Lae-
mmli (35) using a Hoefer gel apparatus.
Immunoblot Analysis—Proteins were separated by SDS-
PAGE and electrophoretically transferred to nitrocellulose
membrane. The nitrocellulose membrane was blocked with 5%
nonfat dry milk in PBS-Tween 20 (0.1%, v/v) at 4 °C overnight.
The membrane was incubated with primary antibody (diluted
according to the manufacturer’s instructions) for 2 h. Horse-
radish peroxidase-conjugated anti-rabbit or anti-mouse IgG
was used as the secondary antibody. Immunoreactive protein
FIGURE 3.Role of the cell cycle in TRAIL sensitivity.DU-145 cells were treatedwith TRAIL (200 ng/ml) for 4 h,
and then detached cells were removed by washing with PBS. Untreated control cells (A) and attached cells (B)
were stained with propidium iodide (PI) and analyzed by a FACScan flow cytometer.
FIGURE 4. Intracellular levels of various anti-apoptotic molecules at 2 days after TRAIL treatment in
DU-145 cells (A), changes in Bcl-xL levels for various times after TRAIL treatment in DU-145 (B) or Mia
PaCa-2 cells (C), and up-regulation of Bcl-xL expression in DU-145 cells (D). Cells were treated with TRAIL
(200 ng/ml) for 4 h and washed out, and then remaining attached cells were incubated for 2 days (2d, A) or
various times (B–D). After incubation, cells were harvested, and Western blot analysis was performed for
detecting various anti-apoptotic molecules including Bcl-xL (A–C). Actin was used to confirm that similar
amounts of proteinswere loaded in each lane. Northern blot analysiswas performed for detecting Bcl-xL. Total
electrolytically fractionated RNAwas probed with the BCL-XL or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA fragment, autoradiographed (upper panel) and analyzed with a densitometer (bottom panel)
(D). Con, control; hIAP, human IAP; t, time.
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was visualized by the chemilumi-
nescence protocol (ECL,Amersham
Biosciences). Quantitation of x-ray
film was carried out by scanning
densitometer (Personal Densitome-
ter, GE Healthcare) using area
integration.
In Vivo Binding of Bcl-xL and Bad
or Bax—To examine the interaction
between Bcl-xL and Bad/Bax,
DU-145 cells in 100-mm culture
plates were transfected with 2 g of
pcDNA3Bad or pcDNA3BadS136A
(kindly provided by Dr. Zieg, Har-
vard Medical School, Boston, MA)
by using Lipofectamine Plus
(Invitrogen) for 2 days. Then the
cells were treated with TRAIL (200
ng/ml) for 4 h, and attached cells
were cultured for 1 or 2 days addi-
tionally. For immunoprecipitation,
cells were lysed in buffer containing
150 mM NaCl, 20 mM Tris-HCl, pH
7.5, 10mM EDTA, 1% Triton X-100,
1% deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride, 80 M
aprotinin, and 2 mM leupeptin, and
the lysates transfected with Bad
were incubated with 1 g of anti-
Bad, or the lysates without transfec-
tion were incubated with anti-Bax
antibody for 2 h. After the addition
of protein G-agarose, the lysates
were incubated for an additional 2 h.
The beads were washed three times
with the lysis buffer, separated by
SDS-PAGE, and immunoblotted
FIGURE 5. TRAIL-induced cytotoxicity, proteolytic cleavage of PARP, and activation of caspases in con-
trol plasmid (pSilencer) or pSilencer-siBcl-xL stably transfectedDU-145 cells. A, immunoblots weremade
of Bcl-xL expression in control vector transfected (pSilencer) or pSilencer-siBcl-xL stably transfected single cell
clones from DU-145 cells. Lysates containing equal amounts of protein (20 g) were separated by SDS-PAGE
and immunoblotted with anti-Bcl-xL antibody. B and C, control plasmid (pSilencer) or pSilencer-siBcl-xL stably
transfected cells (clone #1 or pooled) were treated with TRAIL (200 ng/ml) for 4 h, andmorphological features
of each cell were analyzed with a phase-contrast inverted microscope (upper panels), or cell survival was
determined by trypan blue exclusion assay (lower panels). Error bars represent the S.E. from three separate
experiments. C, control; T, trail.
FIGURE 6. Role of Bcl-xL in the development of acquired TRAIL resistance in DU-145 cells. A–C, control plasmid (pSilencer) or pSilencer-siBcl-xL stably
transfected (siBcl-xL #1 or pooled) cells were first treatedwith 200 ng/ml TRAIL or 10 ng/ml TRAIL for 4 h, respectively, and thenwashed out. The attached cells
were incubated for various days (1–6 days (d)) and then treated a second timewith TRAIL (200 or 10 ng/ml) for 4 h. Cell survival was determined by trypan blue
exclusion assay, and cell lysateswere subjected to immunoblotting for PARP and actin. Actinwas used to confirm that similar amounts of proteinswere loaded
in each lane. Error bars represent the S.E. from three separate experiments. Con, control; t, time.
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with anti-Bcl-xL antibodies. The proteins were detected with
the enhanced chemiluminescence reaction.
Northern Blot Analysis—For Northern blot hybridization,
total RNAs (10 g) isolated from cells were fractionated by
electrophoresis in formaldehyde, 1.2% agarose gels, blotted
onto Nytran Plus (Schleicher & Schuell), and hybridized with
the 32P-labeled BCL-XL or glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) cDNA probe.
Propidium Iodide Staining and Flow Cytometry—Propidium
iodide staining and flow cytometrywere used for cell cycle anal-
ysis. Untreated control cells or attached cells after TRAIL treat-
ment were washed with PBS, then
harvested by trypsinization. Cells
were suspended in PBS containing
2% fetal bovine serum. After wash-
ing again, each cell was resuspended
at 1  106 cells/ml. 3 ml of cold
absolute ethanol was added drop-
wise into 1 ml of cells while gently
vortexing, then cells were kept for
1 h at 4 °C. Fixed cells were spun
down to remove ethanol and
washed twice with PBS, and 1 ml of
propidium iodide staining solution
(50g/ml) containing 0.5mgRNase
A was added. Then cells were incu-
bated in the dark for 3 h at 4 °C and
analyzed by a FACScan flow cytom-
eter (Beckman Coulter, Inc.,
Hialeah, FL).
RESULTS
Development and Decay of
Acquired TRAIL Resistance—We
investigated whether TRAIL resist-
ance develops after TRAIL treat-
ment. In the first step in this study
we examined the time course of
TRAIL-induced cytotoxicity. TRAIL
treatment led to apoptosis, as shown
by cell surface blebbing and the for-
mation of apoptotic bodies (Fig. 1A).
These observations were consistent
with poly(ADP-ribose) polymerase
cleavage (Fig. 1B), which is the hall-
mark featureof apoptosis. Fig. 1A also
shows that50%of the cells died and
were lysed within 4 h of treatment
with 200 ng/ml TRAIL. Interestingly,
repopulation occurred among the
remainingcells.We furtherexamined
whether these repopulated cells had
the same TRAIL sensitivity. DU-145
(Fig. 2, A and B) or MiaPaCa-2 (Fig.
2C) cells were exposed to 200 ng/ml
TRAIL for 4 h, detached cells (90%
dead cells) werewashed out, and then
attached cells were incubated for var-
ious times before being challenged to 200 ng/ml TRAIL for 4 h.
Data from survival assay and Western blot analysis show that
acquired TRAIL resistance developed immediately, was sustained
for 3 days, and then gradually decayed within 6 days in both cell
lines (Fig. 2). These data suggest that acquiredTRAIL resistance is
transient rather than intrinsic.
Role of the Cell Cycle in the Development of Acquired TRAIL
Resistance—Previous studies have shown that cells in theG0/G1
phase are more susceptible to TRAIL than those in the late G1,
S, or G2/M phases (36). It is possible that cell cycle-dependent
differential sensitivity to TRAIL may result in selection of a
FIGURE7.DissociationofBcl-xLfromBadandassociationofBcl-xLwithBaxafterTRAILtreatmentinDU-145
cells.A and B, cells were transfectedwith pcDNA3 vector containingwild-type (wt) Bad ormutant-type (mt;S136A)
Bad.After48hof incubation, cellswere treatedwithTRAIL (200ng/ml) for4h,andthenthe remainingattachedcells
were incubated for various times (0–2 days (d)). Cell lysates were immunoprecipitated (IP) with anti-Bad antibody
(Ab) and immunoblottedwith anti-Bcl-xL or anti-Bad antibody (upper panels). Thepresenceof Bcl-xL, phospho-Akt,
phospho-Bad, or actin in the lysateswas verified by immunoblotting (lower panels). Actinwas used to confirm that
similar amounts of proteins were loaded in each lane. C, cells were transfected with pcDNA3 vector containing
wild-type (wt) Bad ormutant-type (mt;S136A) Bad. After 48 h incubation cells were treatedwith TRAIL (200 ng/ml)
for 4 h (T), and then the remaining attached cells were incubated for 1 day before being challenged to TRAIL (200
ng/ml) for 4 h (T3T). Cell lysateswere subjected to immunoblotting for PARP, caspase-8, and caspase-9. Actinwas
usedtoconfirmthatsimilaramountsofproteinswere loadedineach lane.DandE, cellsweretreatedwithorwithout
TRAIL (200ng/ml) for 4h, and then the remainingattachedcellswere incubated for various times (0–6days)before
harvest. Cell lysateswere immunoprecipitatedwith anti-Bax antibody ormock antibody (IgG) and immunoblotted
with anti-Bcl-xL or anti-Bax antibody (upper panels). The presence of Bcl-xL in the lysates was verified by immuno-
blotting (lower panel). The immunoblotwas analyzedwith a densitometer. Con, control; C, control; T, trail; t, time.
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TRAIL resistant population. This possibility was examined
with cell cycle analysis by comparing untreated control cells
with attached cells after TRAIL treatment. Fig. 3 shows that
TRAIL treatment reduced the G1 population by 5.1% and
increased the G2/M population by 5.7%. These results suggest
that even though TRAIL treatment increases the TRAIL-resis-
tant population, the amount is not significant enough to be
responsible for the development of acquired TRAIL resistance.
Involvement of Bcl-xL in Acquired TRAIL Resistance—We
hypothesized that expression of anti-apoptotic molecules is
responsible for transient TRAIL resistance after TRAIL treat-
ment. To test this hypothesis, the levels of several well known
anti-apoptotic molecules were examined 2 days after TRAIL
treatment. As shown in Fig. 4A, Bcl-xL, which increased by a
factor of 3, was distinctly overexpressed compared with the
other anti-apoptotic molecules. Data from kinetic studies illus-
trate that after TRAIL treatment, the level of Bcl-xL increased
and reached amaximumwithin 2 days and gradually decreased
in both DU-145 and MiaPaCa-2 cells (Fig. 4, B and C). To con-
firm the changes in Bcl-xL expression after TRAIL treatment,
Bcl-xL gene expression was examined various times after treat-
ment with 200 ng/ml TRAIL for 4 h. Fig. 4D shows an increase
in Bcl-xL mRNA immediately after TRAIL treatment of
DU-145 cells. We further examined whether Bcl-xL plays an
important role in the development of acquired TRAIL resist-
ance by using siRNA of Bcl-xL. DU-145 cells were stably trans-
fected with either pSilencer control plasmid or pSilencer-
siBcl-xL vector. We selected several stable transfectants and
chose one transfectant for further studies. Fig. 5A shows that
the expression of Bcl-xL was effectively reduced in the siBcl-xL
#1, #2, #3, and #5. Fig. 5, B and C, show that a single clone
(siBcl-xL #1) and a pool of transfected (siBcl-xL #1, #2, #3, and
#5) cells were sensitive to TRAIL-induced cytotoxicity. TRAIL-
induced proteolytic cleavage of PARP as well as activation of
caspases were increased in a single clone (siBcl-xL #1) and a
pool of transfected cells (data not shown). To examine the
role of Bcl-xL in the development of acquired TRAIL resist-
ance, pSilencer control plasmid-transfected cells, single
clone (siBcl-xL #1) cells, or a pool of transfected cells were
treated for 4 h with 200 or 10 ng/ml (isosurvival dose) of
TRAIL, respectively. After a first TRAIL treatment, detached
cells were removed, and attached cells were incubated vari-
ous times before a second TRAIL treatment. Fig. 6, A–C,
shows that development and decay of acquired TRAIL resist-
ance was observed in pSilencer control plasmid-transfected
cells but not in siBcl-xL #1 and the pool of transfected cells.
Moreover, the second TRAIL treatment enhanced cytotox-
icity in siBcl-xL #1 cells. Similar results were observed with
the pool of transfectants (Fig. 6C). In contrast, overexpres-
sion of Bcl-xL protected cells from TRAIL-induced cytotox-
icity and PARP cleavage as well as activation of caspases
(data not shown).
Evidence for Two Modes of Development of Acquired TRAIL
Resistance—Our results suggest that an increase and decrease
in Bcl-xL level after TRAIL treatment is responsible for the
development and decay of acquired TRAIL resistance. How-
ever, the kinetics of development of acquired TRAIL resistance
does not exactly correspond to the kinetics of elevation of intra-
cellular Bcl-xL level (Fig. 2 and 4, B and C). Immediately after
TRAIL treatment, acquired TRAIL resistance can develop
without a significant increase in Bcl-xL protein level (Fig. 2A).
How can we reconcile this discrepancy? We hypothesized that
two separate pathways are involved in the development of
acquired TRAIL resistance after TRAIL treatment. One is
dependent on the elevation of Bcl-xL level, whichwas described
above. The other is activation of Bcl-xL, achieved by phospho-
rylating Bad so that Bad becomes inactive and can no longer
inhibit Bcl-xL. Previous studies have shown that biologically
active Bad, a pro-apoptotic molecule, is a dephosphorylated
form that interacts with the Bcl-2 or Bcl-xL to inhibit its anti-
apoptotic function (37, 38). In contrast, the inactive formof Bad
is highly phosphorylated and binds to 14-3-3 scaffold proteins
and cannot interact with Bcl-xL (37, 38). We postulated that
association of Bad with Bcl-xL inhibits the biological function
of Bcl-xL, and conversely, dissociation of Bcl-xL from Bad
restores Bcl-xL function. To examine whether interaction
between Bcl-xL and Bad is altered by treatment with TRAIL,
DU-145 cells were treated with 200 ng/ml TRAIL for 4 h and
incubated for 0–2days. Fig. 7A shows that Baddissociated from
Bcl-xL immediately after treatment with TRAIL, and the disso-
ciation was sustained. Fig. 7A also shows that Akt and Bad were
phosphorylated after treatment with TRAIL. We hypothesized
that Bad is phosphorylated by activated (phosphorylated) Akt,
and TRAIL-induced phosphorylation of Bad, through Akt, is
responsible for dissociation of Bad from Bcl-xL. To test the
hypothesis, we employed wild-type Bad against mutant-type
Bad, which cannot be phosphorylated by Akt (39, 40). Fig. 7B
shows that TRAIL treatment dissociated Bcl-xL fromwild-type
Bad but not mutant-type Bad (S136A). Overexpression of
mutant-type Bad (S136A) partially suppressed the develop-
FIGURE 8. Effect of gossypol on TRAIL-induced cytotoxicity in DU-145
cells.Cellswere pretreatedwith 10Mgossypol for 12 h and treatedwith 200
ng/ml TRAIL for 4 h. Cell survival was determined by trypan blue exclusion
assay (A), and cell lysateswere subjected to immunoblotting for PARPor actin
(B). Actinwas used to confirm that similar amounts of proteinswere loaded in
each lane. Error bars represent the S.E. from three separate experiments. con,
control.
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ment of acquired TRAIL resistance (Fig. 7C). After Bcl-xL has
dissociated from Bad, it seems to be associated with Bax (Fig.
7D). Data from densitometer analysis clearly show that an
increase in association of Bax with Bcl-xL occurred before an
increase in the intracellular level of Bcl-xL after TRAIL treat-
ment (Fig. 7E). Previous literatures illustrated that Bcl-xL het-
erodimerizes with Bax, and its heterodimerization abrogates
the biological apoptotic function of Bax (41, 42). Thus, these
results suggest that the final effect of TRAIL-induced acquired
resistance is tomediate the inhibition of the pro-apoptoticmol-
ecule, Bax, by association with Bcl-xL.
Effect of the Bcl-2 Homology 3
(BH3) Mimetic, Gossypol, on De-
velopment of Acquired TRAIL
Resistance—Previous studies have
shown that gossypol, the levorota-
tory isomer of a natural product iso-
lated from cottonseeds and roots,
binds to the BH3 binding groove of
Bcl-xL and Bcl-2 and subsequently
inhibits the heterodimerization of
Bcl-xL or Bcl-2 with proapoptotic
proteins such as Bax, Bad, and
Bcl-xS (43, 44). We hypothesized
that gossypol inhibits development
of acquired TRAIL resistance by
inhibiting interaction between
Bcl-xL and Bax. To test this hypoth-
esis, we first examined the effect of
gossypol on TRAIL cytotoxicity.
Fig. 8 shows that pretreatment with
gossypol enhanced TRAIL-induced
apoptotic death. To investigate the
effect of gossypol in the develop-
ment of acquired TRAIL resistance,
gossypol-pretreated cells were
treatedwith 50 ng/mlTRAIL,which
is the isosurvival dose to 200 ng/ml
TRAIL alone-treated cells. After a
first TRAIL treatment, detached
cells were washed out, and attached
cells were incubated for 1 day in the
presence of gossypol before a sec-
ond TRAIL treatment. Fig. 9, A and
B, show that development of
acquired TRAIL resistance was
suppressed in the presence of gos-
sypol. Moreover, TRAIL-induced
association of Bax with Bcl-xL was
inhibited by treatment with gossy-
pol (Fig. 9C).
Role of Akt in the Development of
Acquired TRAIL Resistance—Our
data in Fig. 7 show that activated
Akt-mediated Bad phosphorylation
is responsible for dissociation of Bad
from Bcl-xL. We further examined
the role of Akt in the development
of acquired TRAIL resistance. Fig. 10A shows a distinctive dif-
ference between attached cells and detached cells. PARP cleav-
age and caspase activation were prominent in detached cells.
Interestingly, TRAIL treatment decreased the level of phospho-
rylated Akt in detached cells. In contrast, phosphorylation of
Akt was increased in attached cells. We hypothesized that
phosphorylation (activation) of Akt plays an important role in
the development of acquired TRAIL resistance. To test our
hypothesis we examined whether inhibition of Akt inhibits the
development of acquired TRAIL resistance. For this study,
LY294002 and wortmannin, inhibitors of phosphatidylinositol
FIGURE 9. Effect of gossypol on the development of acquired TRAIL resistance in DU-145 cells. A, cells
were first treated with TRAIL (200 ng/ml) for 4 h, and then detached cells were removed by washing out with
PBS. After removed detached cells, fresh media were added onto the remaining attached cells and incubated
for 1 day (d) and then treated a second time with TRAIL (200 ng/ml) for 4 h. Cell survival was determined by
trypan blue exclusion assay (upper panel), and cell lysates were subjected to immunoblotting for PARP or actin
(lower panels). Con, untreated control cells. B, cells were pretreated with 10 M gossypol for 12 h and treated
with 50 ng/ml TRAIL for 4 h (lane 3). These cells were washed out and incubated for 1 day in the presence of 10
M gossypol (GP). Cells were then treated with 50 ng/ml TRAIL for 4 h in the presence of 10 M gossypol (lane
4). Cells were treated with only TRAIL (200 ng/ml) for 4 h (lane 2). Cell survival and biochemical assay were
performed as described in Fig. 8A. C, cells were pretreated with 10 M gossypol for 12 h and treated with 50
ng/ml TRAIL for 4 h (lane 4). Cells were treatedwith 200 ng/ml TRAIL for 4 h (lane 3). Cell lysates were immuno-
precipitated (IP)with anti-Baxantibodyormockantibody (IgG) and immunoblottedwithanti-Bcl-xLor anti-Bax
antibody (Ab, upper panels). The presence of Bcl-xL in the lysateswas verified by immunoblotting (lower panel).
Con, untreated control cells. Error bars represent the S.E. from three separate experiments.
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3-kinase, were employed. Fig. 10B shows that the level of phos-
phorylated Akt (attached  detached cells) was somewhat
decreased in TRAIL-treated cells. LY294002 and wortmannin
effectively suppressed the phospho-
rylation of Akt and enhanced
TRAIL-induced apoptotic death.
To further examine the effect of
LY294002 on the development
of acquired TRAIL resistance,
LY294002-pretreated cells were
treatedwith 30 ng/mlTRAIL,which
is the isosurvival dose to 200 ng/ml
TRAIL alone-treated cells. After a
first TRAIL treatment, detached
cells were washed out, and attached
cells were incubated for 1 day in the
presence of LY294002 before a sec-
ond TRAIL treatment. Fig. 10C
shows that development of acquired
TRAIL resistance was inhibited by
treatment with LY294002.
DISCUSSION
In this study we demonstrated
that TRAIL treatment could induce
two states of acquired TRAIL resist-
ance. One is dependent on the ele-
vation of the intracellular level of
Bcl-xL. The other is the restoration
of biological function of Bcl-xL. Our
data show that the latter case plays
an important role in the develop-
ment of acquired TRAIL resistance
in the early stage after TRAIL treat-
ment. The former case is probably
prominent in the later stage. We
also observed that the decay of
acquired TRAIL resistance corre-
sponds to the decrease in the level of
Bcl-xL. These results suggest that
acquired TRAIL resistance is tran-
sient, and it is not due to genetic
alterations.
Previous studies have shown that
Bcl-xL exerts its antiapoptotic func-
tion by inhibiting cytochrome c
release, and overexpression of
Bcl-xL can confer resistance tomost
apoptotic stimuli (45, 46). Bcl-xL
contains four conserved domains,
called BH domains: BH1, BH2, BH3,
and BH4. The three-dimensional
structureofBcl-xL reveals thatBcl-xL
consists of seven amphipathic -heli-
ces joined by flexible loops (47). The
BH domains coincide with -helix
loops and the domains in combina-
tion form the borders of a hydropho-
bic pocket located on the surface of the Bcl-xL protein. The BH1
domain, which coincides with a loop located upstream of the fifth
-helix inBcl-xL, plays an important role indimerizationwithBax
FIGURE 10. Role of Akt in the development of acquired TRAIL resistance inDU-145 cells.A, cells were treated
with TRAIL (200 ng/ml) for 4 h and divided into attached cells and detached cells. Cell lysates were subjected to
immunoblotting for phospho-Akt (pAkt), Akt, PARP, caspase-8, caspase-9, and caspase 3. Actinwasused to confirm
that similar amounts of proteinswere loaded in each lane.d, day. B, cellswere pretreatedwith LY294002 (50M) or
wortmannin (1M) for 1 h followedby TRAIL treatment (200 ng/ml) for 4 h. Cell survival was determined by trypan
blue exclusion assay (upper panel), and cell lysates were subjected to immunoblotting for PARP and pAkt (lower
panels).Actinwasusedtoconfirmthatsimilaramountsofproteinswere loadedineachlane.C, cellswerefirst treated
with TRAIL (200 ng/ml) for 4 h (lane 2) or pretreatedwith LY294002 (50M) for 1 h followedby TRAIL treatment (30
ng/ml) for 4 h (lane 3). And then detached cell were removed by washing out with PBS. Attached cells were incu-
bated for 1day in thepresenceof LY294002 (50M). Cellswere then treated a second timewith TRAIL (30ng/ml) in
thepresenceof LY294002 (50M) for 4h. Cell survivalwasdeterminedby trypanblueexclusionassay (upper panel),
andcell lysateswere subjected to immunoblotting forPARPoractin (lowerpanels).Errorbars represent theS.E. from
three separate experiments. Con, control.
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and results in abrogation of the Bax pro-apoptotic function (41,
42). Protein-protein interaction between the BH3 domain of Bax
and the BH3 binding pocket of Bcl-xL leads to reducing Bax/Bak
formation and prevents mitochondrial membrane permeabiliza-
tion and cytochrome c release. Our data (Fig. 9) and the literature
have demonstrated that small molecular inhibitors such as gossy-
pol, antimycin A, and BH3I-2 (3-iodo-5-chloro-N-[2-chloro-5-
((4-chlorophenyl)sulfonyl)phenyl]-2-hydroxybenzamide), which
bind the BH3 binding pocket of Bcl-xL, block protein-protein
interaction and inhibit the anti-apoptotic function of Bcl-xL
(48–50).
In this study we demonstrated that acquired TRAIL-resis-
tance is probably due to up-regulation of Bcl-xL. Our observa-
tions were similar to previous reports (18). Previous studies
have shown that the transcription factor nuclear factor-B
(NF-B) is critical for the expression of Bcl-xL (51, 52). There
are two functional NF-B DNA binding sites in the upstream
promoter region of Bcl-xL (53, 54). The activation of NF-B
activity is mediated through promoting the phosphorylation
and degradation of the inhibitory subunit IB (55). Although
the expression of Bcl-2 family and IAP family proteins is known
to be regulated by NF-B, our data show that TRAIL treatment
preferentially promotes Bcl-xL gene expression (Fig. 4A). Thus,
a fundamental question that remains unanswered is how
TRAIL treatment selectively promotes the expression of the
Bcl-xL gene among all the Bcl-2 family and IAP family genes. It
is well known that the NF-B family of proteins, including
NF-B1, NF-B2, RelA, RelB, and c-Rel, can form homo- and
heterodimers in vitro, except for RelB. In mammals, the most
widely distributed NF-B is a heterodimer composed of p50
and p65 (also called RelA) subunits (56). NF-B activity is reg-
ulated by the IB family of proteins that interacts with and
sequesters the transcription factor in the cytoplasm. IB pro-
teins become phosphorylated by the multisubunit IB kinase
complex, which subsequently targets IB for ubiquitination
and degradation by the 26 S proteasome (57). At this time only
speculation can be made concerning the role of NF-B in the
up-regulation of Bcl-xL gene expression by treatment with
TRAIL. One possibility is that differential activation of NF-B
may be responsible for selective expression of the Bcl-xL gene.
Previous studies suggest that Bcl-xL is regulated byRelA/p52 or
RelA/p50 rather than p50/p50 or c-Rel/p50 (53, 58, 59). We
believe that many critical questions still remain to be answered
to understand the mechanisms of the regulation of Bcl-xL gene
expression by treatment with TRAIL. However, this model will
provide a framework for future studies.
It is well known that NF-B activity can be regulated through
the phosphatidylinositol 3-kinase-Akt-IB kinase-IB signal
transduction pathway. Phosphatidylinositol 3-kinase consists
of a regulatory subunit (P85) that binds to an activated growth
factor/cytokine receptor and undergoes phosphorylation,
which results in the activation of its catalytic subunit (P110)
(60). Phosphatidylinositol 3-kinase phosphorylates phospho-
inositides at the 3-position of the inositol ring, and its major
lipid product is phosphatidylinositol 3,4,5-triphosphate (61).
Phosphatidylinositol 3,4,5-triphosphate facilitates the recruit-
ment of Akt to the plasmamembrane through binding with the
pleckstrin homology domain of Akt (61). Akt is activated by
phosphoinositide-dependent kinase-1 through phosphoryla-
tion at threonine 308 and serine 473 (62). A number of pro-apo-
ptotic proteins have been identified as direct Akt substrates,
including Bad, caspase-9, and Forkhead transcription factors
(63–68). The pro-apoptotic function of these molecules is sup-
pressed upon phosphorylation byAkt. Recent studies also show
that Akt induces the degradation of IB by promoting IB
kinase activity and subsequently stimulating the nuclear trans-
location of NF-B (69). We observed that TRAIL promotes the
Akt signal transduction pathway through activating (phospho-
rylating) Akt in attached cells but not in detached cells (Figs. 7A
and 10A). Thus, we believe that inactivation of Bad and overex-
pression of Bcl-xL, which play an important role in acquired
TRAIL resistance, occurs by activating Akt and its signal trans-
duction pathway in attached cells. This possibility needs to be
further investigated.
Results from our studies strongly suggest that Bcl-xL is
involved in the development of acquired transient TRAIL
resistance. Nonetheless, wemay not rule out the possibility that
Bcl-xL is not the only molecule that is responsible for develop-
ment of acquired TRAIL resistance. One possibility is down-
regulation of death receptors, DR4 and DR5, during treatment
with TRAIL. Recent studies have revealed that DR5 undergoes
internalization by binding with TRAIL (70). Endocytosis of
death receptors may lead to reduction of cell surface DR4/DR5
and subsequently results in inhibiting the initiation of the death
signal. The other possibility is that cell surface death receptors
of attached cells after TRAIL treatment have an altered signal-
ing capacity that could lead to Akt activation and up-regulation
of Bcl-xL activity. Obviously, these possibilities need to be
examined to understand the mechanism of development of
acquired TRAIL resistance.
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